Weight loss drugs cut cancer risk by 76
A recent study has shown that GLP-1 receptor medications used to treat obesity and diabetes, such as Ozempic, Wegovy, and Mounjaro, may be associated with a reduced risk of certain obesity-related cancers. Reports indicate decreased risks of uterine cancer (76%), ovarian cancer (47%), and meningioma (31%). This is believed to be due to their benefits in weight loss, improving the body's insulin sensitivity, and reducing chronic inflammation—all factors linked to lowering the likelihood of obesity-associated cancers. However, there are warnings about the potential development of thyroid cell tumors, especially in individuals with a family or personal history of such cancers. It is recommended to review medical history with a healthcare provider before starting treatment. To date, studies have not conclusively established an increased risk of pancreatic or colorectal cancers, but ongoing monitoring is advised, particularly for patients with a history of these conditions.
Notice: This Is an AI-Generated Summary
Comments (0)